



scipher
MEDICINE

The Precision Immunology Company

Matching each patient with their most effective therapy

\$552B

wasted in healthcare
due to ineffective
drug spend

10+

years of research
underpin our AI platform
to identify blood-based
therapy selection
biomarkers

5

Prism® tests
launched in 5 years,
starting with
PrismRA in 2021

\$42B

autoimmune
disease TAM

10k+


patients in industry's
largest clinico-genomic
data lake from tested
patients



Prism® blood tests enables payers, PBMs and providers to prescribe existing drugs more effectively.




Clinico-genomic data from tested patients allows pharma to drive precision medicine in preclinical pipeline.



225 million patients are prescribed
drugs they don't respond to.


Response rate for top 10 selling
drugs is below 30%.

\$552 billion in drug spend wasted in complex diseases every year



10x larger problem in complex diseases compared to oncology.

Autoimmune disease is largest contributor to ineffective drug spend



We've unlocked the potential of RNA analysis

Precision Medicine 1.0


DNA



Oncology


Precision Medicine 2.0

RNA (gene expression)



Complex diseases

spectra® identifies patient's unique molecular disease signature from RNA data



Allows us to determine which drug target the patient will respond to.

And develop biomarkers for drug response.

Whole blood RNAseq data from a patient is superimposed on the protein network of human cells and lights up the molecular processes that make up disease biology.

Prism® test pipeline developed in collaboration with payers and PBMs

Therapy selection test starting with autoimmune diseases.

Rheumatoid Arthritis

5m
patients

\$25bn
TAM

Launched 2020

Inflammatory Bowel Disease

2m
patients

\$10bn
TAM

2022 launch

Multiple Sclerosis

1.3m
patients


\$7bn
TAM

In development

The Prism[®] test

A ubiquitous test addressing a \$42bn market opportunity.

One test, multiple diseases and therapies.



We started with the largest opportunity first, anti-TNF drugs

\$33B

annual sales of anti-TNFs,
world's largest drug class.

65%

of patients do **not respond**.



PrismRA[®] blood test predicting non-response to anti-TNFs

90%
prediction
accuracy

Patient
outcomes
improves by
40%

Potential
healthcare
savings of
\$7bn




23-BIOMARKER PANEL


Allows rheumatoid arthritis patients with inadequate response to anti-TNFs to go on cheaper, more effective alternative therapy from day one without unnecessary side effects.

Clinical outcomes studies show reduction in cost while improving outcomes

Reduces cost by 38%




4x more patients respond to therapy




1. Best JH, et al. Rheumatology and Therapy 2020; 7:165-71.
2. Calculated using alternative approved drugs including JAKs, ILs and CDIs.
3. Strand et al. Expert Review of Molecular Diagnostics 2021

15% of providers using test 12 months after launch with 85% repeat ordering rate

Cumulative ordering providers



Repeat ordering



Strong momentum with payers and PBMs 12 months after launch

23

Signed payer/PBM
contracts

Top-3 PBM in the US

Top-5 BCBS plan

Largest health plan GPO

Largest Managed Medicaid plan

Currently accessible to 21 million patients.

PrismIBD[®] to be launched in 2022

+90%
prediction
accuracy


Patient
outcomes
improve by
30%

Potential
healthcare
savings of
\$3B




Predicts response to anti-TNF therapies in **ulcerative colitis patients**

Testing business drives creation of largest patient data lake, monetized through pharma partnerships



**Data lake is growing every day as more patients are tested,
becoming largest in the industry**

Number of patients in data lake




Data lake analyzed by spectra[®] enables precision medicine in preclinical target and drug development



Molecular patient data
from aims[®]



spectra[®] platform
analyzes data



Identifies novel targets specific to
molecularly similar populations, and
biomarkers that select for such patients



Strong data monetization deal value and pipeline

\$0.5bn

In deal value
signed to date

\$1bn

In deal value currently
under negotiation

Pharma and biotech partnerships

\$117m raised to date



khosla ventures



Leadership to bring precision immunology to market



Alif Saleh

Chief Executive Officer

Two successful exits



John Strumbos

Chief Financial Officer

Raised over \$560M in public and private capital



Slava Akmaev, PhD

Chief Technology Officer

Pioneering use of AI in biomarker and drug recovery



Alison Stowell

Chief People Officer

Scaled various stage startup organizations



Chip Parkinson

Chief Commercial Officer

Driven \$1bn+ in annual revenue



Sam Asgarian, MBA, MD

Chief Medical Officer

Former CMO for Thrive. Lead clinical programs for \$1bn+ exit



Sam Davis

General Counsel

Successful \$1.8B SPAC



Lynn Neff

Head of Operations

Built and managed large reference laboratories



Matt Burns

Head of Communications

Led communications for \$8bn exit



120+ employees and growing

Board of advisors



Dr. Regina Benjamin

18th U.S. Surgeon General



Richard Blackburn

Former Global President of
Inflammation & Immunology, Pfizer



Mariann Byerwalter

Chairman Emeritus, SRI Intl
Board of Directors, Pacific Life



Dr. Michael J Elliott

Former SVP of Immunology,
Janssen Pharmaceuticals

We have first mover status in autoimmune diseases

Oncology

Autoimmune



EXACT
SCIENCES

Thrive.

TEMPUS

GRAIL

scipher/
MEDICINE



www.scipher.com